Alexion Pharmaceuticals INC (ALXN) Stake Has Boosted by Bridger Management Llc

March 14, 2018 - By Louis Casey

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It is negative, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Nationwide Fund Advsr has invested 0.1% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Commonwealth Bancorporation Of has 0% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 225 shares. Alexandria Llc has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Cleararc Capital holds 5,721 shares or 0.12% of its portfolio. Congress Asset Mngmt Ma reported 39,028 shares or 0.08% of all its holdings. Premier Asset Management Llc reported 1.72% stake. Caisse De Depot Et Placement Du Quebec invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Manufacturers Life Insurance The, a Ontario – Canada-based fund reported 247,710 shares. Jennison Limited Liability Company invested in 5.33 million shares. Commonwealth Of Pennsylvania Public School Empls Retrmt accumulated 0.04% or 18,151 shares. Canada Pension Plan Board reported 392,696 shares. Sg Americas Ltd Llc owns 96,444 shares. Parametric Limited Liability Company invested 0.11% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Enterprise accumulated 0% or 3 shares. Rainier Invest Mgmt Ltd Liability Corp has invested 0.32% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Since October 2, 2017, it had 0 buys, and 13 selling transactions for $4.63 million activity. Moriarty John B sold $147,865 worth of stock or 1,261 shares. Another trade for 1,459 shares valued at $169,696 was sold by Franchini Indrani Lall. Shares for $556,776 were sold by O’Neill Julie on Tuesday, February 6. Goff Brian also sold $192,028 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. Clancy Paul J had sold 6,079 shares worth $707,048 on Tuesday, February 6. Another trade for 2,553 shares valued at $310,521 was sold by HANTSON LUDWIG.

Roberto Mignone increased its stake in Alexion Pharmaceuticals Inc (ALXN) by 169.47% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc bought 349,114 shares as the company’s stock declined 11.63% while stock markets rallied. The hedge fund run by Roberto Mignone held 555,120 shares of the health care company at the end of 2017Q3, valued at $77.88 million, up from 206,006 at the end of the previous reported quarter. Bridger Management Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be bullish on the $27.20B market cap company. The stock increased 1.32% or $1.6 during the last trading session, reaching $122.68. About 1.20 million shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since March 14, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Bridger Management Llc, which manages about $3.11 billion and $1.67 billion US Long portfolio, decreased its stake in Incyte Corp (NASDAQ:INCY) by 52,772 shares to 315,262 shares, valued at $36.80 million in 2017Q3, according to the filing. It also reduced its holding in Facebook Inc (NASDAQ:FB) by 95,177 shares in the quarter, leaving it with 226,328 shares, and cut its stake in Verisign Inc (NASDAQ:VRSN).

More news for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were recently published by:, which released: “Alexion Pharmaceuticals (ALXN) Shares Cross Above 200 DMA” on March 09, 2018.‘s article titled: “Alexion Ups Its Game With ALXN1210 SC” and published on February 20, 2018 is yet another important article.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was upgraded by Goldman Sachs on Friday, October 28 to “Buy”. The rating was downgraded by Barclays Capital on Monday, September 14 to “Equal Weight”. The stock has “Hold” rating by Jefferies on Wednesday, June 7. Raymond James initiated Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Tuesday, September 1. Raymond James has “Strong Buy” rating and $225.0 target. Leerink Swann maintained the shares of ALXN in report on Tuesday, October 24 with “Buy” rating. On Thursday, August 31 the stock rating was maintained by Jefferies with “Hold”. The company was maintained on Wednesday, December 6 by Leerink Swann. Wedbush maintained the shares of ALXN in report on Friday, October 28 with “Neutral” rating. The firm has “Neutral” rating by Credit Suisse given on Wednesday, January 20. The stock has “Outperform” rating by Raymond James on Thursday, January 4.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: